<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
----------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
DECEMBER 15, 2000
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in its charter)
----------------------------------
ILLINOIS 1-2189 36-0698440
(State or other (Commission File Number) (I.R.S. Employer
Jurisdiction of Identification No.)
Incorporation)
----------------------------------
100 ABBOTT PARK ROAD
ABBOTT PARK, ILLINOIS 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant's telephone number, including area code: (847) 937-6100
----------------------------------
<PAGE>
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
<TABLE>
<CAPTION>
Exhibit No. Exhibit
----------- -------
<S> <C>
Exhibit 99.1 Press Release, dated December 15, 2000 (furnished
pursuant to Item 9).
Exhibit 99.2 Questions and Answers Regarding the Acquisition of
the Pharmaceutical Business of BASF (Furnished
Pursuant to Item 9).
</TABLE>
ITEM 9. REGULATION FD DISCLOSURE
The information contained in Exhibits 99.1 and 99.2 is incorporated
herein by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
ABBOTT LABORATORIES
/s/ Gary P. Coughlan
------------------------------
By: Gary P. Coughlan
Senior Vice President, Finance and Chief
Financial Officer
Date: December 18, 2000
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit No. Exhibit
----------- -------
<S> <C>
99.1 Press Release, dated December 15, 2000 (furnished pursuant
to Item 9).
99.2 Questions and Answers Regarding the Acquisition of the
Pharmaceutical Business of BASF (Furnished Pursuant to Item 9).
</TABLE>
